Ocular manifestations of systemic inflammatory diseases

Connecticut Medicine

Volumn 76, Issue 9, 2012, Pages 533-544

  Mohsenin, Amir ^a   Huang, John J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; COGAN SYNDROME; EYE DISEASE; HUMAN; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; RELAPSING POLYCHONDRITIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BEHCET SYNDROME; COGAN SYNDROME; EYE DISEASES; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYCHONDRITIS, RELAPSING; SJOGREN'S SYNDROME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84868008746     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Aletaha D, Neogi T, Silman AJ, et al: 2010 Rheumatoid arthritis classification criteria: An american college of rheumatology/ european league against rheumatism collaborative initiative. Arthritis Rheum 2010; 62( 9): 2569-81.
2. Fujita M, Igarashi T, Kurai T, et al: Correlation between dry eye and rheumatoid arthritis activity. AmJ Ophthalmol 2005; 140(5):808-13. (Pubitemid 41727672)
3. Riley GP, Harrall RL, Watson PG, et al: Collagenase (MMP1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye (Lonad) 1995; 9(Pt 6):703-18. (Pubitemid 26018194)
4. Sainz de la Maza M, Molina N, Gonzales LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 2012;
5. Foster CS, Forstet SL, Wilson LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91( 10): 1253-63.
6. Nishimura K, Sugiyama D, Kogata Y, et al: Meta-analysis: Diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med/2007;146(11):797-808. (Pubitemid 351650500)
7. Noecker R: Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18( 5): 205-15.
8. Stevenson D, Tauber J, Reis BL: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderateto-severe dry eye disease: A dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 2000; 107( 5): 967-74.
9. Emery P, Breedveld FC, Hall S, et al: Comparison of methotrexate monotherapy with a combination or methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008; 372( 9636): 375-82.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al: The premier study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54( 1): 26-37.
11. Cervera R, Khamashta MA, Font J, et al: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82(5):299-308. (Pubitemid 37229465)
12. Alarcon GS, McGwin G, Jr., Petri M, et al: Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11(2):95-101. (Pubitemid 34259439)
13. Hochberg MC: Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40( 9): 1725.
14. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum 1982; 25(11):1271-7. (Pubitemid 13221242)
15. Jensen JL, Bergem HO, Gilboe IM, et al: Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. J Oral Pathol Med 1999; 28(7):317-22. (Pubitemid 29332334)
16. Gold DH, Morris DA, Henkind P: Ocular findings in systemic lupus erythematosus. BrJ Ophthalmol 1972; 56( 11): 800-4.
17. Klinkhoff AV, Beattie CW, Chalmers A: Retinopathy in systemic lupus erythematosus: Relationship to disease activity. Arthritis Rheum 1986; 29(9):1152-6. (Pubitemid 16017807)
18. Ushiyama O, Ushiyama K, Koarada S, et al: Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59( 9): 705-8.
19. Nguyen QD, Uy HS, Akpek EK, et al: Choroidopathy of systemic lupus erythematosus. Lupus 2000; 9(4):288-98. (Pubitemid 30261071)
20. Jabs DA, Miller NR, Newman SA, et al: Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 1986; 104(4):564-8. (Pubitemid 16086345)
21. Avina-Zubieta JA. Galindo-Rodriguez G, Kwan-Yeung L, et al: Clinical evaluation of various selected elisa kits for the detection of anti-DNA antibodies. Lupus 1995; 4( 5): 370-4.
22. Wilson WA, Gharavi AE, Koike T, et al: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42(7):1309-11. (Pubitemid 30265586)
23. Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). JThrombHaemost 2006; 4( 2): 295-306.
24. Galli M, Luciani D, Bertolini G, et al: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101(5):1827-32. (Pubitemid 36237580)
25. Leo-Kotder B, Klein R, Berg PA, et al: Ocular symptoms in association with antiphospholipid antibodies. Graefes Arch Clin Exp Ophthalmol 1998; 236(9):658-68. (Pubitemid 28427176)
26. Miserocchi E, Baltatzis S, Foster CS: Ocular features associated with anticardiolipin antibodies: A descriptive study. Am J Ophthalmol 2001;131(4):451-6. (Pubitemid 32273431)
27. Giorgi D, Gabrieli CB, Bonomo L: The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm 1998; 6(4):269-73. (Pubitemid 29043750)
28. Herbort CP, Rao NA, Mochizuki M: International criteria for the diagnosis of ocular sarcoidosis: Results of the first international workshop on ocular sarcoidosis (TWOS). Ocul Immunol Inflamm 2009; 17( 3): 160-9.
29. Rybicki BA, Major M, Popovich J, Jr., et al: Racial differences in sarcoidosis incidence: A 5 -year study in a health maintenance organization. Am J Epidemiol 1997; 145( 3): 234-41.
30. Heiligenhaus A, Wefelmeyer D, Wefelmeyer E, et al: The eye as a common site for the early clinical manifestation of sarcoidosis. Ophthalmic Res 2011; 46( 1): 9-12.
31. Thomas KW, Hunninghake GW: Sarcoidosis. JAMA 2003; 289(24):3300-3. (Pubitemid 37430085)
32. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/ WASOG statement on sarcoidosis. american thoracic society/european respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vase Diffuse Lung Dis 1999; 16( 2): 149-73.
33. Baughman RP.Teirstein AS Judson MA, et al: Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Grit Care Med 2001; 164(10 Pt l):1885-9. (Pubitemid 33152325)
34. Helmick CG, Felson DT, Lawrence RC, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58( 1): 15-25.
35. Kunert KS. Tisdale AS, Stern ME, et al: Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118( 11): 1489-96.
36. Fox RI, Chan R, Michelson JB, et al: Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27(4):459-61. (Pubitemid 14134788)
37. Kassan SS,Thomas TL, Moutsopoulos HM, et al: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89(6):888-92. (Pubitemid 9087322)
38. Zufferey P, Meyer OC, Grossin M, et al: Primary Sjogren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 1995; 24(6):342-5. (Pubitemid 26041934)
39. Isaak BL, Liesegang TJ, Michet CJ, Jr.: Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986; 93(5):681-9. (Pubitemid 16086722)
40. McAdam LP, O'Hanlan MA, Bluestone R, et al: Relapsing polychondritis: Prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55( 3): 193-215.
41. Kent PD,Michet CJ, Jr., Luthra HS: Relapsing polychondritis. Curr Opin Rheumatol 2004; 16(1):56-61. (Pubitemid 38041400)
42. Falk RJ, Gross WL, Guillevin L, et al: Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63( 4): 863-4.
43. Leavitt RY, Fauci AS, Bloch DA, et al: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33(8): 1101-7. (Pubitemid 20273294)
44. Seo P, Stone JH: The antineutrophil cytoplasmic antibodyassociated vasculitides. Am J Med 2004; 117( 1): 39-50.
45. Bullen CL, Liesegang TJ, McDonald TJ, et al: Ocular complications of Wegener s granulomatosis. Ophthalmology 1983; 90( 3): 279-90.
46. Hoffman GS, Kerr GS, Leavitt RY, et al: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116( 6): 488-98.
47. Jones RB, Tervaert JW, Hauser T, et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Eng J Med 2010; 363( 3): 211-20.
48. Stone JH, Merkel PA, Spiera R, et al: Rituximab vs cyclophosphamide for ANCA-associated vasculitis. NEngl J Med 2010; 363( 3): 221-32.
49. Pagnoux C, Seror R, Henegar C, et al: Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the french vasculitis study group database. Arthritis Rheum 2010; 62( 2): 616-26.
50. Lightfoot RW, Jr., Michel BA, Bloch DA, et al: The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa.Arthritis Rheum 1990; 33(8):1088-93. (Pubitemid 20273292)
51. Wise GN: Ocular periarteritis nodosa: Report of two cases. AMA Arch Ophthalmol 1952; 48( 1): 1-11.
52. Guillevin L, Lhotě F, Cohen P, et al: Polyarteritis nodosa related to hepatitis B virus. A prospective study with longterm observation of 41 patients. Medicine (Baltimore) 1995; 74( 5): 238-53.
53. Ramos-Casals M, Munoz S, Medina F, et al: Systemic autoimmune diseases in patients with hepatitis C virus infection: Characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36( 7): 1442-8.
54. Leib ES, Restivo C, Paulus HE: Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67(6):941-7. (Pubitemid 10194551)
55. Ayusawa M, Sonobe T, Uemura S, et al: Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47( 2): 2321.
56. Fujiwara H, Hamashima Y: Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61(1):100-7. (Pubitemid 8268802)
57. Kato H, Ichinose E, Kawasaki T: Myocardial infarction in Kawasaki disease: Clinical analyses in 195 casts. J Pediatr 1986; 108(6):923-7. (Pubitemid 16096813)
58. Tsuda E, Hirata T, Matsuo O, et al: The 30-year outcome for patins after myocardial infarction due to coronary artery esions caused by Kawasaki disease. Pediatr Cardiol 2011; 32( 2): 176-82.
59. Burns JC, Shike H, Gordon JB, et al: Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28(1):253-7. (Pubitemid 26266648)
60. Germain BF, Moroney JD, Guggino GS, et al: Anterior uveitis in kawasaki disease. J Pediatr 1980; 97( 5): 780-l.
61. Newburger JW, Takahashi M, Beiser AS, et al: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324( 23): 1633-9.
62. Behcet H, Matteson EL: On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol 2010; 28( 4 Suppl 60): S2-5.
63. Ohno S, Ohguchi M, Hirose S, et al: Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982; 100(9): 1455-8. (Pubitemid 12055531)
64. Atmaca LS: Fundus changes associated with behcet's disease. Graefes Arch Clin Exp Ophthalmol 1989; 227( 4): 340-4.
65. Barra C, Beifort Junior R, Abreu MT, et al: Behcet's disease in brazil-a review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 1991; 35( 3): 339-46.
66. Mishima S, Masuda K, Izawa Y, et al: The eighth Frederick H. Verhoeff Lecture, presented by saiichi mishima, MD Behcet's disease in Japan: Ophthalmologic aspects. Trans Am Ophthalmol Soc 1979; 77:225-79. (Pubitemid 10072809)
67. Schotland DL. WolfSM, White HH, et al: Neurologic aspects of behcet's disease. case report and review of the literature. Am J Med 1963; 34: 544-53.
68. Criteria for diagnosis of behcet's disease. international study group for behcet's disezse. Lancet 1990; 335( 8697): 1078-80.
69. Cogan DG: Syndrome ofnonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthalmol 1945; 33( 144).
70. Norton EW, Cogan DG: Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms; A long-term follw-up. AMA Arch Ophthalmol 1959; 61( 5): 695-7.
71. Grasland A, Pouchot J, Hachulla E, et al: Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology (Oxford) 2004; 43(8):1007-15. (Pubitemid 39144448)
72. Vollertsen RS, McDonald TJ, Younge BR, et al: Cogan's syndrome: Eighteen cases and a review of the literature. Mayo Clin Proc 1986; 61(5):344-61. (Pubitemid 16016435)
73. Cochrane AD, Tatoulis J: Cogan's syndrome with aortitis, aortic regurgitation, and aortic arch vessel stenoses. Ann Thorac Surg 1991; 52( 5): 1166-7.
74. Gasparovic H, Djuric Z, Bosnic D, et al: Aortic root vasculitis associated with Cogan's syndrome. Ann Thorac Surg 2011; 92( 1): 340-1.
75. Kondo Y, Ito S, Ohi Y, et al: Atypical cogan's syndrome with aortitis. Intern Med 2009; 48( 12): 1093-7.
76. Darougar S, John AC, Viswalingam M, et al: Isolation of Chlamydia psittaci from a patient with interstitial keratitis and uveitis associated with otological and cardiovascular lesions. BrJ Ophthalmol 1978; 62(10): 709-14. (Pubitemid 8399470)
77. Lepur D,Vranjican Z, Himbele J,et al:Chlarnydia pneumoniae infection as a trigger for a Cogan's syndrome. J Infect 2006; 52(3):223-6. (Pubitemid 43286189)
78. Shah P, Luqmani RA,Murray PI, et al: Posterior scleritis-An unusual manifestation of Cogan's syndrome. Br J Rheumatol 1994; 33(8)774-5. (Pubitemid 24249189)
79. Mazlumzadeh M, Matteson EL: Cogan's syndrome: An audiovestibular, ocular, and systemic autoimmune disease. Rheum Dis Clin North Am 2007; 33(4):855-74, vii-viii. (Pubitemid 350122974)
80. Gluth MB, Baratz KH, Matteson EL, et al: Cogan syndrome: A retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006; 81( 4): 483-8.